CGAS and neoplasm: Simultaneously, preclinical animal models must also be optimized, as the molecular mechanism by which cGAS-STING combined with bispecific antibodies mediates NK cell killing of tumor cells can be more accurately explored in humanized animal models with a functional human immune system.